Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Protect Against Dox Cardiotoxicity in Myeloma
Protect Against Dox Cardiotoxicity in Myeloma
Does vitamin C protect against DOX Cardiotoxicity in Myeloma? Yes, according to the research linked below. Unfortunately, I’ll never know myself because I learned about preventing chemo-induced cardiotoxicity long after I was diagnosed with this potentially fatal side effect of docorubicin, aka DOX.
Heart damage caused by chemotherapy is a common side effect. Cardiotoxicity has been known about for decades. As new chemo regimens have been developed, a growing number of studies have been conducted to identify this problem.
While I was prescribed many cardiotoxic regimens, including doxorubicin (Adriamycin), I was not told about the probable side effects nor were there any preventative therapies available at the time.
Managing Chemotherapy-Induced Cardiomyopathy
If you have been diagnosed with multiple myeloma and you are undergoing Adriamycin/doxorubicin, consider supplementing with vitamin C. I wish I had when I underwent VAD as my induction therapy.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing your MM or any of your short or long-term side effects with both conventional and non-conventional therapies.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Vitamin C as a Cardioprotective Agent Against Doxorubicin- Induced Cardiotoxicity
ABSTRACT: ‘
Doxorubicin is used and highly effective chemotherapeutic agent; however, its clinical utility remains limited by dose-dependent cardiotoxicity, presenting a significant challenge in cancer management. Growing preclinical research and clinical evidence suggest that the antioxidant vitamin C (ascorbic acid) may confer cardioprotective effects against doxorubicin-induced cardiotoxicity.
In this review, both preclinical and clinical research has been synthesized to assess the potential role of vitamin C in mitigating doxorubicin- induced cardiotoxicity. Preclinical data have routinely indicated that vitamin C can reduce oxidative stress, preserve mitochondrial function, and modulate proinflammatory cytokine levels. Additionally, animal models have demonstrated promising results in maintaining cardiomyocyte structural integrity.
In this capacity, vitamin C may be an effective adjunctive therapeutic for attenuating cardiac injury. Conversely, the clinical data remain variable, with emerging evidence supporting the notion that vitamin C can serve as a safe adjunct that preserves cardiac function during anthracycline therapy. Further investigation is warranted to optimize dosing, timing, and delivery routes and better elucidate the exact molecular mechanisms of these protective effects. This review emphasizes key molecular mechanisms, such as oxidative and nitrosative stress, mitochondrial dysfunction, and inflammatory signaling, in the myocardium, and examines the role of vitamin C supplementation, alone or in combination with doxorubicin, on myocardial damage markers and cardiomyocyte viability…
VITAMIN C IMPACT ON DOXORUBICIN- INDUCED CARDIOTOXICITY
In exploring the critical impact of vitamin C supplementation on DIC, a growing body of research has investigated the dynamic relationship between doxorubicin and the potential protective effects of vitamin C on cardiac function (Figure 2). Additional studies have examined its potential as a prophylactic measure against DIC.72 Both animal and clinical studies have suggested that vitamin C may confer protective benefits and improve cardiac function when administered alongside doxorubicin treatment.73 However, responses to vitamin C supplementation vary among individuals, with factors such as the dose, timing relative to doxorubicin administration, preexisting cardiovascular conditions, and cancer type influencing effectiveness.73 By ex-ample, Sacks et al reported that, in H9c2 myoblast, mitochondrial- targeted antioxidants like mitoquinone and SKQ1, not vitamin C, were effective in the mitigation of doxorubicin- induced damage.74
protect against DOX Cardiotoxicity in Myeloma protect against DOX Cardiotoxicity in Myeloma protect against DOX Cardiotoxicity in Myeloma